Sentien Biotechnologies Announces Open IND in Phase 1/2 Trial of SBI-101 for Patients with COVID-19
/
DateAug 18 2020
Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for the evaluation of Sentien’s lead asset, SBI-101, for the treatment of severe COVID-19. Read More →

















